Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 678 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $11.6B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $21.9M in total
- 5
- 13F holdersQ2 2026, +41 vs. previous quarter
- 678
- 13F valueReported value at the end of Q2 2026
- $9.62B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.40B
- +37.6% year over year
- Net income, FY2025
- $316.9M
- −28.6% year over year
- Free cash flow, FY2025
- $644.6M
- +37.6% year over year
- Revenue, Q3 FY2026
- $493.0M
- +39.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 13.7M
- Shares sold short
- Change
- −4.01K
- 0.0% vs. previous
- Days to cover
- 6.81
- At average daily volume
Superinvestors holding HALO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding HALO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Halozyme Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 (view filing)7:56 PM ET | Oct 6-8 | 2 days | Torley HelenPRESIDENT AND CEO | SSale | −60.0K | $110.18 | −$6.61M | −7.2%767.8K after | 12 lots10b5-1 |
| Oct 2, 2026 (view filing)4:38 PM ET | Oct 1 | 1 day | Posard Matthew L.Director | SSale | −5.23K | $108.54 | −$567.7K | −8.9%53.6K after | 4 lots10b5-1 |
| Sep 17, 2026 (view filing)5:19 PM ET | Sep 16 | 1 day | Posard Matthew L.Director | SSale | −19.0K | $107.74 | −$2.05M | −24.4%58.8K after | 4 lots10b5-1 |
| Sep 11, 2026 (view filing)8:35 PM ET | Sep 9-11 | 2 days | Torley HelenPRESIDENT AND CEO | SSale | −60.0K | $107.28 | −$6.44M | −7.2%767.8K after | 7 lots10b5-1 |
| Aug 19, 2026 (view filing)8:01 PM ET | Aug 17-19 | 2 days | Torley HelenPRESIDENT AND CEO | SSale | −60.0K | $104.59 | −$6.28M | −7.2%767.8K after | 11 lots10b5-1 |
| Aug 11, 2026 (view filing)5:43 PM ET | Aug 10 | 1 day | Connaughton BernadetteDirector | SSale | −1.63K | $102.80 | −$167.2K | −3.9%40.4K after | 10b5-1 |
| Jul 9, 2026 (view filing)5:19 PM ET | Jul 8 | 1 day | Torley HelenPRESIDENT AND CEO | SSale | −1.92K | $79.77 | −$153.4K | −0.2%767.8K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)4:42 PM ET | Jul 1 | 1 day | Connaughton BernadetteDirector | SSale | −1.63K | $76.71 | −$124.7K | −3.7%42.0K after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Krishnan MaheshDirector | SSale | −7.30K | $75.00 | −$547.8K | −33.6%14.5K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1-3 | 2 days | Torley HelenPRESIDENT AND CEO | SSale | −50.0K | $67.40 | −$3.37M | −6.1%767.8K after | 9 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 678 holdersThe largest institutional positions in Halozyme Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,271,095 | $1.04B | 0.02% | +6,0420.0% | Added |
| Vanguard Capital Management LLC | 5,351,312 | $418.8M | 0.01% | +80,094+1.5% | Added |
| Vanguard Portfolio Management LLC | 5,299,008 | $414.8M | 0.02% | +49,802+0.9% | Added |
| State Street Corp | 5,179,434 | $405.4M | 0.01% | +241,580+4.9% | Added |
| Invesco Ltd. | 3,177,997 | $248.7M | 0.02% | −834,497−20.8% | Reduced |
| Morgan Stanley | 2,832,594 | $221.7M | 0.01% | +270,285+10.5% | Added |
| Boston Partners | 2,773,568 | $216.8M | 0.19% | +89,885+3.3% | Added |
| Bank of America Corp | 2,740,561 | $214.5M | 0.01% | −172,548−5.9% | Reduced |
| Geode Capital Management, LLC | 2,519,951 | $197.3M | 0.01% | +14,165+0.6% | Added |
| William Blair Investment Management, LLC | 2,511,050 | $196.5M | 0.59% | −14,925−0.6% | Reduced |
Holders of 5% or more of HALO
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Halozyme Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 10.20%12.6M shares | −2.90 ppfrom 13.10% | Apr 28, 20252 filings | Jul 17, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 5.21%6.17M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
Politician trades
All politician trades in HALO3 members of Congress reported 10 trades in Halozyme Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Oct 12, 2026 |  Gilbert Ray Cisneros, Jr. House · CA | Sell (partial) | $1K-$15K |
| Apr 7, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Apr 7, 2025 | Gilbert Ray Cisneros, Jr. House · CA | Sell (partial) | $1K-$15K |
| Oct 3, 2024 |  Josh Gottheimer House · NJ | Sell (partial) | $1K-$15K |
| Aug 13, 2023 |  Daniel S. Goldman House · NY | Sell | $15K-$50K |
House · CA · Oct 12, 2026
Sell (partial)$1K-$15K
House · CA · Apr 7, 2026
Buy$1K-$15K
House · CA · Apr 7, 2025
Sell (partial)$1K-$15K
House · NJ · Oct 3, 2024
Sell (partial)$1K-$15K
House · NY · Aug 13, 2023
Sell$15K-$50K